Market capitalization | $110.36m |
Enterprise Value | $112.12m |
P/E (TTM) P/E ratio | 12.30 |
EV/FCF (TTM) EV/FCF | 3.37 |
EV/Sales (TTM) EV/Sales | 0.51 |
P/S ratio (TTM) P/S ratio | 0.50 |
P/B ratio (TTM) P/B ratio | 2.25 |
Revenue growth (TTM) Revenue growth | -4.77% |
Revenue (TTM) Revenue | $219.14m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
3 Analysts have issued a Puma Biotechnology, Inc. forecast:
3 Analysts have issued a Puma Biotechnology, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 219 219 |
5%
5%
|
|
Gross Profit | 160 160 |
9%
9%
|
|
EBITDA | 31 31 |
20%
20%
|
EBIT (Operating Income) EBIT | 20 20 |
32%
32%
|
Net Profit | 8.72 8.72 |
457%
457%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Head office | United States |
CEO | Alan Auerbach |
Employees | 185 |
Founded | 2010 |
Website | www.pumabiotechnology.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.